Menu Search
Equities

MustGrow Biologics Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0C0:FRA

MustGrow Biologics Corp

Actions
  • Price (EUR)0.37
  • Today's Change-0.012 / -3.14%
  • Shares traded21.00k
  • 1 Year change-60.39%
  • Beta0.6226
Data delayed at least 15 minutes, as of Feb 11 2026 07:07 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

MustGrow Biologics Corp. is a fully integrated provider of biological and regenerative agriculture solutions designed to support sustainable farming. The Company's proprietary and third-party product lines offer eco-friendly alternatives to restricted or banned synthetic chemicals and fertilizers. In North America, it offers a portfolio of third-party crop nutrition solutions, including micronutrients, nitrogen stabilizers, biostimulants, and foliar products. It develops mustard-based organic solutions for applications in biocontrol to potentially replace harmful synthetic chemicals in preplant soil treatment and weed control, to postharvest disease control and food preservation. Its TerraSante is Organic Materials Review Institute (OMRI Listed) and Organic Input Material (OIM) registered biofertility product in California, Florida, Arizona, Idaho, Oregon, and Washington. TerraSante provides mustard proteins and carbohydrates to feed the soil microbes.

  • Revenue in CAD (TTM)7.54m
  • Net income in CAD-6.37m
  • Incorporated2014
  • Employees0.00
  • Location
    MustGrow Biologics Corp1005-201 1st Ave SSaskatoon S7K 1J5CanadaCAN
  • Phone+1 (306) 668-2652
  • Websitehttps://mustgrow.ca/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.